title: Perioperative haemostatic management of haemophilic mice using normal mouse plasma.
abstract: Intense haemostatic interventions are required to avoid bleeding complications when surgical procedures are performed on haemophilia patients. The objective of this study was to establish an appropriate protocol for perioperative haemostatic management of haemophilic mice. We assessed the prophylactic haemostatic effects of normal mouse plasma (NMP) on haemophilia B (HB) mice for both a skin flap procedure and a laparotomy. When 500 μL of NMP was administered to the mice, plasma factor IX (FIX:C) levels peaked at 15.1% immediately after intravenous (IV) administration, at 6.1% 2 h after intraperitoneal (IP) administration and at 2.7% 6 h after subcutaneous administration. Administering 500 μL of NMP via IP or IV 30 min in advance enabled the skin flap procedure to be performed safely without any complications. After the laparotomy procedure, several mice in the IP administration group exhibited lethal bleeding, but all mice survived in the IV administration group. Anti-mouse FIX inhibitors did not develop, even after repetitive administrations of NMP. However, human FIX concentrates, especially plasma-derived concentrates, elicited the anti-human FIX inhibitors. The results show that administering 500 μL of NMP via IV or IP 30 min in advance enables surgical procedures to be safely performed on HB mice, and that IV administration is more desirable than IP if the procedure requires opening of the abdominal wall.
authors.affiliation: Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, Shinjuku, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Tatsumi
authors.forename: K
authors.initials: K
authors.lastname: Ohashi
authors.forename: K
authors.initials: K
authors.lastname: Kanegae
authors.forename: I K
authors.initials: IK
authors.lastname: Shim
authors.forename: T
authors.initials: T
authors.lastname: Okano
mesh_terms: D000818:Animals; D019774:Blood Coagulation Factor Inhibitors / Q000378:metabolism; D062109:Dermatologic Surgical Procedures / Q000401:mortality; D005164:Factor IX / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism; D002836:Hemophilia B / Q000209:etiology*; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D019990:Perioperative Care; D015996:Survival Rate
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D005164:Factor IX
keywords: haemophilia; haemostatic management; inhibitor; mice; normal mouse plasma; operation